Trial Profile
An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoma; Leiomyosarcoma; Malignant melanoma; Malignant thymoma; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours; Synovial sarcoma; Thymoma
- Focus Therapeutic Use
- Acronyms RESOUND
- 09 Sep 2022 Status changed from active, no longer recruiting to completed.
- 27 Oct 2021 Primary endpoint has been met (activity of regorafenib screening, in terms of 2-months progression free survival rate) as per Results published in the Cancer
- 27 Oct 2021 Results published in the Cancer